Actively Recruiting
B.Subtilis Attenuate Symptoms in Diarrhea-predominant Irritable Bowel Syndrome by Increasing Hypoxanthine Biosynthesis
Led by Jinling Hospital, China · Updated on 2024-09-25
180
Participants Needed
2
Research Sites
30 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a prospective, single-blind, randomized parallel study to investigate whether B. subtilis could improve clinical symptoms of IBS-D patients. Patients are randomly assigned by envelope method. A senior gastroenterologist is responsible for prescribing medication. Researchers are blind to patients' medication. Participants with IBS are recruited and randomized to receive a 4-week administration of B. subtilis-based probiotics. Clinical symptoms and stool samples are collected before and after the trial.
CONDITIONS
Official Title
B.Subtilis Attenuate Symptoms in Diarrhea-predominant Irritable Bowel Syndrome by Increasing Hypoxanthine Biosynthesis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients diagnosed with irritable bowel syndrome based on Rome IV criteria
- Age between 16 and 80 years old
- No gut medical conditions such as inflammatory bowel diseases, infectious diarrhea, or colon tumors
You will not qualify if you...
- Taking probiotics, proton pump inhibitors, antibiotics, or drugs affecting uric acid levels within one month before the study
- Decline to participate in the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Jinling Hospital
Nanjing, China
Actively Recruiting
2
Jinling Hospital
Nanjing, China
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here